Physician profile
Sheldon T Warman
NPI 1508821786
$5,911.66
in general payments reported to CMS, 2019-2025
28 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $290 · 2021: $588 · 2022: $505 · 2023: $969 · 2024: $1,456 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,044.31 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $737.61 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $690.23 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Heartflow, INC. | $579.85 | 2022-2025 | Ffrct |
| Pfizer INC. | $442.99 | 2021-2025 | |
| Amarin Pharma, INC. | $411.71 | 2019-2023 | |
| Novo Nordisk INC | $276.74 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $266.64 | 2020-2025 | Nexletol |
| Edwards Lifesciences Corporation | $221.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $164.67 | 2020-2025 | |
| Abbvie INC. | $154.44 | 2021-2024 | Dalvance |
| Gilead Sciences, INC. | $147.53 | 2019 | |
| Stryker Corporation | $141.14 | 2024 | |
| Lilly USA, LLC | $88.89 | 2024-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $88.24 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.61 | 2021 | |
| Exact Sciences Corporation | $54.29 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.23 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $47.97 | 2019-2023 | Xarelto |
| Abbott Laboratories | $47.52 | 2023-2024 | Eterna |
| Medtronic, INC. | $39.34 | 2024 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $33.42 | 2021 | |
| Agepha Pharma Fz LLC | $28.30 | 2025 | Lodoco |
| Almatica Pharma LLC | $25.05 | 2023 | Loreev Xr |
| Corium, LLC | $19.26 | 2023 | Azstarys |
| Spinal Simplicity, LLC | $16.66 | 2024 | Ha Minuteman G3-R |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2022 | |
| Eisai INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Warman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.